STEMCO Biomedical, Inc. is a biotechnology company founded in 1999 and based in one of the world’s most prolific biotechnology regions, Research Triangle Park, North Carolina. The company was founded by world-class researchers at the Duke University Comprehensive Cancer Center and Stem Cell Transplant Program. These researchers developed STEMCO’s core technology over several years of studied research and active participation in transplanting stem cells into cancer patients. Stemco is now known as Aldegen.
















Led by CEO Jim Petrilla, a graduate of the U.S. Naval Academy and seasoned life-sciences executive, the company has grown its management team by adding a group of talented business and research executives with an average of 15 years of experience in their fields of expertise. Currently, STEMCO is housed in an 11,000 sq.ft. facility in Durham, NC and has grown to a total of 26 employees.

STEMCO is engaged in the development and manufacture of hematopoietic stem cell (HSC) identification products, and they have a clearly defined product development and release strategy.

The market for the products being developed by STEMCO is very large; the transplant market alone is more than $1 billion annually. In addition, there are no high profile ethical concerns with the use of STEMCO’s products since the products use traditional and widely-accepted sources of HSCs that are not derived from fetal or embryonic tissues. The expanded applications of STEMCO’s platform technology will include autoimmune diseases, anemias, tissue regeneration and cell plasticity. These additional applications give STEMCO access to markets in excess of $5 billion annually.

STEMCO's mission is to be the leader in therapeutic stem cell products for cancer treatment and regenerative medicine applications.

STEMCO BIO Corporate Profile Video (Choose a speed 56K, DSL/Cable, Broadband)

STEMCO Biomedical, Inc. is a member of the Council for Entrepreneurial Development.